{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:02:32Z","timestamp":1792000952015,"version":"4.4.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jacc.2017.09.028","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T16:45:46Z","timestamp":1508777146000},"page":"2278-2289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":610,"title":["Interleukin-1 Beta as a Target for Atherosclerosis\u00a0Therapy"],"prefix":"10.1016","volume":"70","author":[{"given":"Peter","family":"Libby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.09.028_bib1","series-title":"Atheroclerosis Reviews","first-page":"79","article-title":"Inflammatory and immune mechanisms in atherogenesis","author":"Libby","year":"1990"},{"key":"10.1016\/j.jacc.2017.09.028_bib2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","article-title":"Adaptive immunity in atherogenesis: new insights and therapeutic approaches","volume":"123","author":"Lichtman","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/joim.12406","article-title":"Inflammation and plaque vulnerability","volume":"278","author":"Hansson","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.116.301313","article-title":"Inflammation and immunity in diseases of the arterial tree: players and layers","volume":"116","author":"Libby","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/1744666X.2016.1195686","article-title":"Immune-mediated mechanisms of atherosclerosis and implications for the clinic","volume":"12","author":"Nus","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib7","article-title":"Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups \u201cAtherosclerosis and Vascular Biology\u201d and \u201cThrombosis\u201d","volume":"116","author":"Weber","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2017.09.028_bib8","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"History of discovery: inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.111.075929","article-title":"Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative","volume":"125","author":"Cook","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A\u00a0Test in Context: High-Sensitivity C-Reactive Protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib12","doi-asserted-by":"crossref","first-page":"II18","DOI":"10.1161\/01.CIR.0000129505.34151.23","article-title":"Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?","volume":"109","author":"Schonbeck","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/ATVBAHA.113.301925","article-title":"Regulation of an inflammatory disease: Kruppel-like factors and atherosclerosis","volume":"34","author":"Jain","year":"2014","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jacc.2016.12.005","article-title":"Trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries","volume":"69","author":"Masoudi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib18","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2017.09.028_bib19","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1172\/JCI37346","article-title":"Many cytokines are very useful therapeutic targets in disease","volume":"118","author":"Feldmann","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.110.207415","article-title":"Recent advances on the role of cytokines in atherosclerosis","volume":"31","author":"Ait-Oufella","year":"2011","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1084\/jem.153.5.1215","article-title":"Demonstration of a human pyrogen-inducing factor during mixed leukocyte reactions","volume":"153","author":"Dinarello","year":"1981","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib22","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","article-title":"Nucleotide sequence of human monocyte interleukin-1 precursor cDNA","volume":"81","author":"Auron","year":"1984","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"10.1016\/j.jacc.2017.09.028_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib24","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","article-title":"Interleukin-1 induces interleukin-1. I. Induction of circulating interleukin-1 in rabbits in\u00a0vivo and in human mononuclear cells in\u00a0vitro","volume":"139","author":"Dinarello","year":"1987","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib25","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.4049\/jimmunol.139.6.1911","article-title":"Interleukin-1 induces interleukin-1. II. Recombinant human interleukin-1 induces interleukin-1 production by adult human vascular endothelial cells","volume":"139","author":"Warner","year":"1987","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152474","article-title":"Redundancy of IL-1 isoform signaling and its implications for arterial remodeling","volume":"11","author":"Beltrami-Moreira","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2017.09.028_bib27","first-page":"251","article-title":"Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 \u03b2-converting enzyme","volume":"147","author":"Geng","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2017.09.028_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molmed.2016.12.007","article-title":"Inflammasome priming in sterile inflammatory disease","volume":"23","author":"Patel","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nri1997","article-title":"Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation","volume":"7","author":"Mariathasan","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2017.09.028_bib32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2017.09.028_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2017.09.028_bib34","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Paramel Varghese","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2017.09.028_bib35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCULATIONAHA.113.002714","article-title":"Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility","volume":"128","author":"Xiao","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCULATIONAHA.113.004390","article-title":"Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis","volume":"128","author":"Abe","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.115.304437","article-title":"Moderate hypoxia potentiates interleukin-1beta production in activated human macrophages","volume":"115","author":"Folco","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib38","doi-asserted-by":"crossref","first-page":"13410","DOI":"10.1074\/jbc.M112.426254","article-title":"Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome","volume":"288","author":"Rajamaki","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2017.09.028_bib39","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.108.772491","article-title":"Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist","volume":"117","author":"Fearon","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF03261881","article-title":"Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events","volume":"26","author":"Abbate","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.jacc.2017.09.028_bib41","first-page":"393","article-title":"Interleukin-1 activation of vascular endothelium effects on procoagulant activity and leukocyte adhesion","volume":"121","author":"Bevilacqua","year":"1985","journal-title":"Am J Path"},{"key":"10.1016\/j.jacc.2017.09.028_bib42","first-page":"179","article-title":"Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells","volume":"124","author":"Libby","year":"1986","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2017.09.028_bib43","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1172\/JCI112732","article-title":"Inducible interleukin-1 expression in human vascular smooth muscle cells","volume":"78","author":"Libby","year":"1986","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1172\/JCI113346","article-title":"Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids","volume":"88","author":"Libby","year":"1988","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI114498","article-title":"Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin-6","volume":"85","author":"Loppnow","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib46","first-page":"588","article-title":"Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response","volume":"61","author":"Le","year":"1989","journal-title":"Lab Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.1840120517","article-title":"Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6","volume":"12","author":"Castell","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2017.09.028_bib48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.09.028_bib49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Hingorani","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.09.028_bib50","doi-asserted-by":"crossref","first-page":"I308","DOI":"10.1161\/hc37t1.094871","article-title":"Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis","volume":"104","author":"Suzuki","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027923","article-title":"Alterations in the interleukin-1\/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse","volume":"6","author":"Abbate","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2017.09.028_bib52","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/eurheartj\/ehu369","article-title":"Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?","volume":"36","author":"Abbate","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in\u00a0vivo. The role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cardiores.2005.06.026","article-title":"Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model","volume":"68","author":"Morton","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.CIR.97.3.242","article-title":"Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice","volume":"97","author":"Elhage","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib59","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/01.CIR.0000142085.39015.31","article-title":"Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and\/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications","volume":"110","author":"Chi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cardiores.2005.01.008","article-title":"Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice","volume":"66","author":"Merhi-Soussi","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.191.2.303","article-title":"Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene","volume":"191","author":"Nicklin","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib62","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ajpath.2011.11.028","article-title":"Deficiency of interleukin-1 receptor antagonist promotes spontaneous femoral artery aneurysm formation in mice","volume":"180","author":"Isoda","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2017.09.028_bib63","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/01.ATV.0000127025.48140.a3","article-title":"Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice","volume":"24","author":"Isoda","year":"2004","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1172\/JCI43713","article-title":"Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice","volume":"122","author":"Alexander","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib65","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.4049\/jimmunol.143.12.4015","article-title":"Activated platelets express IL-1 activity","volume":"143","author":"Hawrylowicz","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib66","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.4049\/jimmunol.1001623","article-title":"Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles","volume":"186","author":"Brown","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI61163","article-title":"IL-1 and atherosclerosis: a murine twist to an evolving human story","volume":"122","author":"Rader","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib68","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2017.09.028_bib69","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10637-015-0226-6","article-title":"Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer","volume":"33","author":"Hong","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jacc.2017.09.028_bib71","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib72","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib73","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacc.2017.09.028_bib74","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib77","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib78","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib79","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib81","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamacardio.2016.0604","article-title":"Informative neutral studies matter\u2014why the targeting inflammation with salsalate in cardiovascular disease (TINSAL-CVD) trial deserves our attention","volume":"1","author":"Ridker","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib82","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"White","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.09.028_bib84","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2015.02.012","article-title":"Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial","volume":"169","author":"O'Donoghue","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib85","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: a randomized clinical trial","volume":"315","author":"O'Donoghue","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.09.028_bib86","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.09.028_bib87","unstructured":"Tardif J-C, L'Allier P. Colchicine Cardiovascular Outcomes Trial (COLCOT). 2017. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02551094?term=colcot&rank=1. Accessed October 10, 2017."},{"key":"10.1016\/j.jacc.2017.09.028_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib89","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacc.2017.09.028_bib90","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib91","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20011022","article-title":"Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis","volume":"195","author":"Gerdes","year":"2002","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib93","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nm.3890","article-title":"Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter","volume":"21","author":"Wang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib94","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1089\/ars.2014.5989","article-title":"The inflammasome in myocardial injury and cardiac remodeling","volume":"22","author":"Toldo","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jacc.2017.09.028_bib95","first-page":"828","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.09.028_bib96","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2017.09.028_bib97","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.94.5.1931","article-title":"Functional CD 40 Ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis","volume":"94","author":"Mach","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2017.09.028_bib98","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2017.09.028_bib99","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1357-2725(00)00016-9","article-title":"CD154 (CD40 ligand)","volume":"32","author":"Schonbeck","year":"2000","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jacc.2017.09.028_bib100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib101","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1073\/pnas.97.13.7464","article-title":"Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype","volume":"97","author":"Lutgens","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2017.09.028_bib102","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1038\/mtna.2015.40","article-title":"CD40 generation 2.5 antisense oligonucleotide treatment attenuates doxorubicin-induced nephropathy and kidney inflammation","volume":"4","author":"Donner","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacc.2017.09.028_bib103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/ci500631e","article-title":"Discovery of small molecule CD40-TRAF6 inhibitors","volume":"55","author":"Zarzycka","year":"2015","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.jacc.2017.09.028_bib104","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4049\/jimmunol.142.1.100","article-title":"Human vascular smooth muscle cells. Target for and source of tumor necrosis factor","volume":"142","author":"Warner","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib105","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jacc.2017.09.028_bib106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1097-2765(00)80139-2","article-title":"Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice","volume":"2","author":"Gu","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.jacc.2017.09.028_bib107","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1172\/JCI5624","article-title":"MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B","volume":"103","author":"Gosling","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2017.09.028_bib108","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/29788","article-title":"Decreased lesion formation in CCR2-\/- mice reveals a role for chemokines in the initiation of atherosclerosis","volume":"394","author":"Boring","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2017.09.028_bib109","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2017.09.028_bib110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure","volume":"339","author":"Swirski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jacc.2017.09.028_bib111","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2015.12.048","article-title":"Leukocytes link local and systemic inflammation in ischemic cardiovascular disease","volume":"67","author":"Libby","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2017.09.028_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0026-2015","article-title":"Mechanisms of myeloid cell modulation of atherosclerosis","volume":"4","author":"Swirski","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jacc.2017.09.028_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.09.028_bib114","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10555-010-9229-0","article-title":"Why not treat human cancer with interleukin-1 blockade?","volume":"29","author":"Dinarello","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jacc.2017.09.028_bib115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.RES.75.1.181","article-title":"Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion","volume":"75","author":"Galis","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib116","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/2159-8290.CD-12-0101","article-title":"Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling","volume":"2","author":"Li","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jacc.2017.09.028_bib117","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/CIRCULATIONAHA.115.016160","article-title":"Targeting Interleukin-1beta Reduces Leukocyte Production After Acute Myocardial Infarction","volume":"132","author":"Sager","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.09.028_bib118","doi-asserted-by":"crossref","first-page":"342ra80","DOI":"10.1126\/scitranslmed.aaf1435","article-title":"RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction","volume":"8","author":"Sager","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib119","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/CIRCRESAHA.115.307523","article-title":"Murine \u201cmodel\u201d monotheism: an iconoclast at the altar of mouse","volume":"117","author":"Libby","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.09.028_bib120","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1084\/jem.165.5.1316","article-title":"Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells","volume":"165","author":"Warner","year":"1987","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacc.2017.09.028_bib121","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0008-8749(89)90095-6","article-title":"Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1","volume":"122","author":"Loppnow","year":"1989","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jacc.2017.09.028_bib122","doi-asserted-by":"crossref","first-page":"19569","DOI":"10.1074\/jbc.272.31.19569","article-title":"Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta","volume":"272","author":"Schoenbeck","year":"1997","journal-title":"J\u00a0Biol Chem"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717397796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717397796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T08:44:39Z","timestamp":1693125879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717397796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":122,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0735109717397796"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.09.028","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1 Beta as a Target for Atherosclerosis\u00a0Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}